Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.8963 |
High Similarity |
NPD1509 |
Clinical (unspecified phase) |
0.8462 |
Intermediate Similarity |
NPD7390 |
Discontinued |
0.8156 |
Intermediate Similarity |
NPD651 |
Clinical (unspecified phase) |
0.8151 |
Intermediate Similarity |
NPD2532 |
Approved |
0.8151 |
Intermediate Similarity |
NPD2533 |
Approved |
0.8151 |
Intermediate Similarity |
NPD2534 |
Approved |
0.8129 |
Intermediate Similarity |
NPD943 |
Approved |
0.812 |
Intermediate Similarity |
NPD1201 |
Approved |
0.8112 |
Intermediate Similarity |
NPD970 |
Clinical (unspecified phase) |
0.8015 |
Intermediate Similarity |
NPD1470 |
Approved |
0.8014 |
Intermediate Similarity |
NPD1607 |
Approved |
0.7902 |
Intermediate Similarity |
NPD1510 |
Phase 2 |
0.7872 |
Intermediate Similarity |
NPD1240 |
Approved |
0.7847 |
Intermediate Similarity |
NPD5406 |
Approved |
0.7847 |
Intermediate Similarity |
NPD5404 |
Approved |
0.7847 |
Intermediate Similarity |
NPD5405 |
Approved |
0.7847 |
Intermediate Similarity |
NPD5408 |
Approved |
0.7785 |
Intermediate Similarity |
NPD7422 |
Clinical (unspecified phase) |
0.7771 |
Intermediate Similarity |
NPD6959 |
Discontinued |
0.7727 |
Intermediate Similarity |
NPD7819 |
Suspended |
0.7677 |
Intermediate Similarity |
NPD8443 |
Clinical (unspecified phase) |
0.7671 |
Intermediate Similarity |
NPD1552 |
Clinical (unspecified phase) |
0.7671 |
Intermediate Similarity |
NPD1550 |
Clinical (unspecified phase) |
0.7669 |
Intermediate Similarity |
NPD405 |
Clinical (unspecified phase) |
0.7667 |
Intermediate Similarity |
NPD4378 |
Clinical (unspecified phase) |
0.7619 |
Intermediate Similarity |
NPD1549 |
Phase 2 |
0.7613 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.761 |
Intermediate Similarity |
NPD6232 |
Discontinued |
0.7578 |
Intermediate Similarity |
NPD7473 |
Discontinued |
0.75 |
Intermediate Similarity |
NPD4196 |
Clinical (unspecified phase) |
0.75 |
Intermediate Similarity |
NPD1164 |
Approved |
0.7484 |
Intermediate Similarity |
NPD7411 |
Suspended |
0.7483 |
Intermediate Similarity |
NPD1551 |
Phase 2 |
0.745 |
Intermediate Similarity |
NPD2800 |
Approved |
0.7448 |
Intermediate Similarity |
NPD230 |
Phase 1 |
0.7436 |
Intermediate Similarity |
NPD1934 |
Approved |
0.7419 |
Intermediate Similarity |
NPD4380 |
Phase 2 |
0.741 |
Intermediate Similarity |
NPD9269 |
Phase 2 |
0.7397 |
Intermediate Similarity |
NPD6651 |
Approved |
0.7391 |
Intermediate Similarity |
NPD5711 |
Approved |
0.7391 |
Intermediate Similarity |
NPD5710 |
Approved |
0.7372 |
Intermediate Similarity |
NPD9268 |
Approved |
0.7368 |
Intermediate Similarity |
NPD1511 |
Approved |
0.7365 |
Intermediate Similarity |
NPD2935 |
Discontinued |
0.7355 |
Intermediate Similarity |
NPD3226 |
Approved |
0.732 |
Intermediate Similarity |
NPD7410 |
Clinical (unspecified phase) |
0.7301 |
Intermediate Similarity |
NPD7852 |
Clinical (unspecified phase) |
0.7279 |
Intermediate Similarity |
NPD9493 |
Approved |
0.7273 |
Intermediate Similarity |
NPD1512 |
Approved |
0.7273 |
Intermediate Similarity |
NPD4750 |
Phase 3 |
0.725 |
Intermediate Similarity |
NPD7075 |
Discontinued |
0.7248 |
Intermediate Similarity |
NPD2796 |
Approved |
0.7226 |
Intermediate Similarity |
NPD920 |
Approved |
0.7222 |
Intermediate Similarity |
NPD1247 |
Approved |
0.7197 |
Intermediate Similarity |
NPD74 |
Approved |
0.7197 |
Intermediate Similarity |
NPD9266 |
Approved |
0.7197 |
Intermediate Similarity |
NPD6599 |
Discontinued |
0.719 |
Intermediate Similarity |
NPD643 |
Clinical (unspecified phase) |
0.7188 |
Intermediate Similarity |
NPD3882 |
Suspended |
0.7174 |
Intermediate Similarity |
NPD9545 |
Approved |
0.7171 |
Intermediate Similarity |
NPD3750 |
Approved |
0.7171 |
Intermediate Similarity |
NPD1878 |
Clinical (unspecified phase) |
0.717 |
Intermediate Similarity |
NPD2801 |
Approved |
0.717 |
Intermediate Similarity |
NPD7096 |
Clinical (unspecified phase) |
0.7143 |
Intermediate Similarity |
NPD6559 |
Discontinued |
0.7133 |
Intermediate Similarity |
NPD6099 |
Approved |
0.7133 |
Intermediate Similarity |
NPD6100 |
Approved |
0.7132 |
Intermediate Similarity |
NPD846 |
Approved |
0.7132 |
Intermediate Similarity |
NPD940 |
Approved |
0.7121 |
Intermediate Similarity |
NPD9267 |
Approved |
0.7121 |
Intermediate Similarity |
NPD9264 |
Approved |
0.7121 |
Intermediate Similarity |
NPD9263 |
Approved |
0.7121 |
Intermediate Similarity |
NPD9265 |
Clinical (unspecified phase) |
0.7105 |
Intermediate Similarity |
NPD7421 |
Clinical (unspecified phase) |
0.7105 |
Intermediate Similarity |
NPD1243 |
Approved |
0.7099 |
Intermediate Similarity |
NPD919 |
Approved |
0.7097 |
Intermediate Similarity |
NPD642 |
Clinical (unspecified phase) |
0.7086 |
Intermediate Similarity |
NPD2346 |
Discontinued |
0.7081 |
Intermediate Similarity |
NPD7768 |
Phase 2 |
0.7078 |
Intermediate Similarity |
NPD3300 |
Phase 2 |
0.7071 |
Intermediate Similarity |
NPD2932 |
Approved |
0.7071 |
Intermediate Similarity |
NPD3019 |
Approved |
0.7067 |
Intermediate Similarity |
NPD3299 |
Clinical (unspecified phase) |
0.7066 |
Intermediate Similarity |
NPD5844 |
Phase 1 |
0.7037 |
Intermediate Similarity |
NPD3749 |
Approved |
0.7032 |
Intermediate Similarity |
NPD6799 |
Approved |
0.7 |
Intermediate Similarity |
NPD6801 |
Discontinued |
0.6988 |
Remote Similarity |
NPD6166 |
Phase 2 |
0.6988 |
Remote Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.6988 |
Remote Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.6964 |
Remote Similarity |
NPD6020 |
Phase 2 |
0.6951 |
Remote Similarity |
NPD5494 |
Approved |
0.695 |
Remote Similarity |
NPD4626 |
Approved |
0.6948 |
Remote Similarity |
NPD6398 |
Clinical (unspecified phase) |
0.6944 |
Remote Similarity |
NPD1283 |
Approved |
0.6933 |
Remote Similarity |
NPD4381 |
Clinical (unspecified phase) |
0.6918 |
Remote Similarity |
NPD9494 |
Approved |
0.6914 |
Remote Similarity |
NPD3817 |
Phase 2 |
0.6892 |
Remote Similarity |
NPD411 |
Approved |
0.6884 |
Remote Similarity |
NPD9281 |
Approved |
0.6883 |
Remote Similarity |
NPD2654 |
Approved |
0.6879 |
Remote Similarity |
NPD1651 |
Approved |
0.6864 |
Remote Similarity |
NPD7804 |
Clinical (unspecified phase) |
0.6863 |
Remote Similarity |
NPD2344 |
Approved |
0.6863 |
Remote Similarity |
NPD1471 |
Phase 3 |
0.6842 |
Remote Similarity |
NPD3748 |
Approved |
0.6842 |
Remote Similarity |
NPD2799 |
Discontinued |
0.6824 |
Remote Similarity |
NPD7074 |
Phase 3 |
0.6822 |
Remote Similarity |
NPD288 |
Approved |
0.6818 |
Remote Similarity |
NPD9261 |
Approved |
0.6806 |
Remote Similarity |
NPD9717 |
Approved |
0.6805 |
Remote Similarity |
NPD3818 |
Discontinued |
0.6802 |
Remote Similarity |
NPD4419 |
Clinical (unspecified phase) |
0.6796 |
Remote Similarity |
NPD7501 |
Clinical (unspecified phase) |
0.6794 |
Remote Similarity |
NPD1242 |
Phase 1 |
0.6784 |
Remote Similarity |
NPD5953 |
Discontinued |
0.678 |
Remote Similarity |
NPD7879 |
Clinical (unspecified phase) |
0.6779 |
Remote Similarity |
NPD3764 |
Approved |
0.6779 |
Remote Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.6768 |
Remote Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.6765 |
Remote Similarity |
NPD7054 |
Approved |
0.6761 |
Remote Similarity |
NPD5691 |
Approved |
0.6748 |
Remote Similarity |
NPD1465 |
Phase 2 |
0.6744 |
Remote Similarity |
NPD844 |
Approved |
0.6743 |
Remote Similarity |
NPD8150 |
Discontinued |
0.6736 |
Remote Similarity |
NPD1281 |
Approved |
0.6735 |
Remote Similarity |
NPD6917 |
Clinical (unspecified phase) |
0.6731 |
Remote Similarity |
NPD4628 |
Phase 3 |
0.6731 |
Remote Similarity |
NPD7003 |
Approved |
0.6725 |
Remote Similarity |
NPD7472 |
Approved |
0.6711 |
Remote Similarity |
NPD4625 |
Phase 3 |
0.6708 |
Remote Similarity |
NPD5808 |
Clinical (unspecified phase) |
0.6708 |
Remote Similarity |
NPD7458 |
Discontinued |
0.669 |
Remote Similarity |
NPD3972 |
Approved |
0.6688 |
Remote Similarity |
NPD2309 |
Approved |
0.6686 |
Remote Similarity |
NPD6797 |
Phase 2 |
0.6667 |
Remote Similarity |
NPD1699 |
Clinical (unspecified phase) |
0.6667 |
Remote Similarity |
NPD3026 |
Approved |
0.6667 |
Remote Similarity |
NPD1203 |
Approved |
0.6667 |
Remote Similarity |
NPD3023 |
Approved |
0.6667 |
Remote Similarity |
NPD7286 |
Phase 2 |
0.6647 |
Remote Similarity |
NPD7251 |
Discontinued |
0.6645 |
Remote Similarity |
NPD447 |
Suspended |
0.6643 |
Remote Similarity |
NPD3024 |
Approved |
0.6643 |
Remote Similarity |
NPD3025 |
Approved |
0.6623 |
Remote Similarity |
NPD520 |
Approved |
0.6623 |
Remote Similarity |
NPD6663 |
Approved |
0.6622 |
Remote Similarity |
NPD2798 |
Approved |
0.6619 |
Remote Similarity |
NPD7635 |
Approved |
0.6618 |
Remote Similarity |
NPD2342 |
Discontinued |
0.6615 |
Remote Similarity |
NPD1809 |
Phase 2 |
0.6611 |
Remote Similarity |
NPD6535 |
Approved |
0.6611 |
Remote Similarity |
NPD6534 |
Approved |
0.6609 |
Remote Similarity |
NPD7808 |
Phase 3 |
0.6585 |
Remote Similarity |
NPD37 |
Approved |
0.6577 |
Remote Similarity |
NPD5736 |
Approved |
0.6573 |
Remote Similarity |
NPD8397 |
Clinical (unspecified phase) |
0.6571 |
Remote Similarity |
NPD5035 |
Approved |
0.6556 |
Remote Similarity |
NPD6410 |
Clinical (unspecified phase) |
0.6556 |
Remote Similarity |
NPD2313 |
Discontinued |
0.6556 |
Remote Similarity |
NPD3268 |
Approved |
0.6556 |
Remote Similarity |
NPD4907 |
Clinical (unspecified phase) |
0.6541 |
Remote Similarity |
NPD289 |
Clinical (unspecified phase) |
0.6532 |
Remote Similarity |
NPD1729 |
Discontinued |
0.6531 |
Remote Similarity |
NPD4749 |
Approved |
0.6531 |
Remote Similarity |
NPD1755 |
Approved |
0.6529 |
Remote Similarity |
NPD3926 |
Phase 2 |
0.6525 |
Remote Similarity |
NPD5951 |
Approved |
0.6522 |
Remote Similarity |
NPD6779 |
Approved |
0.6522 |
Remote Similarity |
NPD6780 |
Approved |
0.6522 |
Remote Similarity |
NPD6776 |
Approved |
0.6522 |
Remote Similarity |
NPD6778 |
Approved |
0.6522 |
Remote Similarity |
NPD6782 |
Approved |
0.6522 |
Remote Similarity |
NPD6781 |
Approved |
0.6522 |
Remote Similarity |
NPD6777 |
Approved |
0.6519 |
Remote Similarity |
NPD8166 |
Discontinued |
0.6519 |
Remote Similarity |
NPD3400 |
Discontinued |
0.6514 |
Remote Similarity |
NPD4338 |
Clinical (unspecified phase) |
0.6508 |
Remote Similarity |
NPD8151 |
Discontinued |
0.6507 |
Remote Similarity |
NPD1610 |
Phase 2 |
0.6507 |
Remote Similarity |
NPD1547 |
Clinical (unspecified phase) |
0.6507 |
Remote Similarity |
NPD422 |
Phase 1 |
0.6506 |
Remote Similarity |
NPD5402 |
Approved |
0.6503 |
Remote Similarity |
NPD7700 |
Phase 2 |
0.6503 |
Remote Similarity |
NPD7699 |
Phase 2 |
0.6488 |
Remote Similarity |
NPD6234 |
Discontinued |
0.6486 |
Remote Similarity |
NPD1876 |
Approved |
0.6481 |
Remote Similarity |
NPD6980 |
Clinical (unspecified phase) |
0.6481 |
Remote Similarity |
NPD5403 |
Approved |
0.6477 |
Remote Similarity |
NPD8312 |
Approved |
0.6477 |
Remote Similarity |
NPD8313 |
Approved |
0.6475 |
Remote Similarity |
NPD4141 |
Clinical (unspecified phase) |
0.6471 |
Remote Similarity |
NPD2979 |
Phase 3 |
0.6471 |
Remote Similarity |
NPD7229 |
Phase 3 |
0.6467 |
Remote Similarity |
NPD4966 |
Approved |
0.6467 |
Remote Similarity |
NPD4965 |
Approved |
0.6467 |
Remote Similarity |
NPD4967 |
Phase 2 |
0.6463 |
Remote Similarity |
NPD1608 |
Approved |
0.6462 |
Remote Similarity |
NPD845 |
Approved |
0.646
|
Remote Similarity |
NPD5401 |
Approved |